- Home
- TRUG vs EDSA Comparison
TRUG vs EDSA Comparison
Compare TRUG & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- EDSA
- Stock Information
- Founded
- TRUG 1983
- EDSA 2015
- Country
- TRUG United States
- EDSA Canada
- Employees
- TRUG N/A
- EDSA N/A
- Industry
- TRUG
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- TRUG
- EDSA Health Care
- Exchange
- TRUG NYSE
- EDSA Nasdaq
- Market Cap
- TRUG 7.0M
- EDSA 13.8M
- IPO Year
- TRUG N/A
- EDSA N/A
- Fundamental
- Price
- TRUG $5.30
- EDSA $2.18
- Analyst Decision
- TRUG Strong Buy
- EDSA Strong Buy
- Analyst Count
- TRUG 1
- EDSA 2
- Target Price
- TRUG $100.00
- EDSA $13.00
- AVG Volume (30 Days)
- TRUG 74.8K
- EDSA 22.9K
- Earning Date
- TRUG 08-13-2025
- EDSA 08-08-2025
- Dividend Yield
- TRUG N/A
- EDSA N/A
- EPS Growth
- TRUG N/A
- EDSA N/A
- EPS
- TRUG N/A
- EDSA N/A
- Revenue
- TRUG $22,236,072.00
- EDSA N/A
- Revenue This Year
- TRUG $9.66
- EDSA N/A
- Revenue Next Year
- TRUG $48.94
- EDSA N/A
- P/E Ratio
- TRUG N/A
- EDSA N/A
- Revenue Growth
- TRUG 8.40
- EDSA N/A
- 52 Week Low
- TRUG $5.00
- EDSA $1.55
- 52 Week High
- TRUG $73.50
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- TRUG 30.21
- EDSA 60.86
- Support Level
- TRUG $5.00
- EDSA $1.89
- Resistance Level
- TRUG $5.67
- EDSA $2.23
- Average True Range (ATR)
- TRUG 0.49
- EDSA 0.11
- MACD
- TRUG 0.11
- EDSA 0.02
- Stochastic Oscillator
- TRUG 10.53
- EDSA 85.29
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games (including Links, a sports game for PC), hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.